Influence of noncompliance with radiation therapy protocol guidelines and operative bed recurrences for children with rhabdomyosarcoma and microscopic residual disease: a report from the Children's Oncology Group
- PMID: 20646841
- PMCID: PMC4462166
- DOI: 10.1016/j.ijrobp.2010.01.058
Influence of noncompliance with radiation therapy protocol guidelines and operative bed recurrences for children with rhabdomyosarcoma and microscopic residual disease: a report from the Children's Oncology Group
Abstract
Purpose: Postoperative radiation therapy (RT) is recommended for patients with rhabdomyosarcoma having microscopic disease. Sometimes RT dose/volume is reduced or omitted in an attempt to avoid late effects, particularly in young children. We reviewed operative bed recurrences to determine if noncompliance with RT protocol guidelines influenced local-regional control.
Methods and materials: All operative bed recurrences among 695 Group II rhabdomyosarcoma patients in Intergroup Rhabdomyosarcoma Study Group (IRS) I through IV were reviewed for deviation from RT protocol. Major/minor dose deviation was defined as >10% or 6-10% of the prescribed dose (40-60 Gy), respectively. Major/minor volume deviation was defined as tumor excluded from the RT field or treatment volume not covered by the specified margin (preoperative tumor volume and 2- to 5-cm margin), respectively. No RT was a major deviation.
Results: Forty-six of 83 (55%) patients with operative bed recurrences did not receive the intended RT (39 major and 7 minor deviations). RT omission was the most frequent RT protocol deviation (19/46, 41%), followed by dose (17/46, 37%), volume (9/46, 20%), and dose and volume deviation (1/46, 2%). Only 7 operative bed recurrences occurred in IRS IV (5% local-regional failure) with only 3 RT protocol deviations. Sixty-three (76%) patients with recurrence died of disease despite retrieval therapy, including 13 of 19 nonirradiated children.
Conclusion: Over half of the operative bed recurrences were associated with noncompliance; omission of RT was the most common protocol deviation. Three fourths of children die when local-regional disease is not controlled, emphasizing the importance of RT in Group II rhabdomyosarcoma.
Copyright © 2011 Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of interest: none
Figures


Similar articles
-
Patterns of Failure in Pediatric Rhabdomyosarcoma After Proton Therapy.Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1070-1077. doi: 10.1016/j.ijrobp.2016.08.028. Epub 2016 Aug 30. Int J Radiat Oncol Biol Phys. 2016. PMID: 27742542
-
Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study.Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):720-6. doi: 10.1016/j.ijrobp.2011.06.2011. Epub 2011 Nov 19. Int J Radiat Oncol Biol Phys. 2012. PMID: 22104356 Free PMC article. Clinical Trial.
-
Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma.Int J Radiat Oncol Biol Phys. 2021 Mar 1;109(3):718-725. doi: 10.1016/j.ijrobp.2020.09.050. Int J Radiat Oncol Biol Phys. 2021. PMID: 33516439
-
Volumetric considerations in radiotherapy for pediatric parameningeal rhabdomyosarcomas.Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1294-9. doi: 10.1016/s0360-3016(02)04290-6. Int J Radiat Oncol Biol Phys. 2003. PMID: 12654440 Review.
-
Outcome and Patterns of Relapse in Childhood Parameningeal Rhabdomyosarcoma Treated With Proton Beam Therapy.Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):1043-1054. doi: 10.1016/j.ijrobp.2019.08.005. Epub 2019 Aug 13. Int J Radiat Oncol Biol Phys. 2019. PMID: 31419513 Review.
Cited by
-
Advances in the management of pediatric genitourinary rhabdomyosarcoma.Transl Androl Urol. 2020 Oct;9(5):2441-2454. doi: 10.21037/tau-20-480. Transl Androl Urol. 2020. PMID: 33209718 Free PMC article. Review.
-
Whole Lung Irradiation in Rhabdomyosarcoma With Lung Metastases: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group.J Clin Oncol. 2024 Dec 20;42(36):4263-4270. doi: 10.1200/JCO.24.00928. Epub 2024 Sep 10. J Clin Oncol. 2024. PMID: 39255438
-
Do children and adolescents with completely resected alveolar rhabdomyosarcoma require adjuvant radiation? A report from the Children's Oncology Group.Pediatr Blood Cancer. 2020 May;67(5):e28243. doi: 10.1002/pbc.28243. Epub 2020 Mar 2. Pediatr Blood Cancer. 2020. PMID: 32124549 Free PMC article. Clinical Trial.
-
Delayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.Int J Cancer. 2015 Jul 1;137(1):204-11. doi: 10.1002/ijc.29351. Epub 2014 Dec 10. Int J Cancer. 2015. PMID: 25418440 Free PMC article.
-
Radiotherapy quality assurance report from children's oncology group AHOD0031.Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):1065-71. doi: 10.1016/j.ijrobp.2014.11.034. Epub 2015 Feb 7. Int J Radiat Oncol Biol Phys. 2015. PMID: 25670539 Free PMC article. Clinical Trial.
References
-
- Smith LM, Anderson JR, Qualman S, et al. Which patients with rhabdomyosarcoma (RMS) and microscopic residual tumor (Group II) fail therapy? A report from the soft tissue sarcoma committee of the Children’s Oncology Group. J Clin Oncol. 2001;19:4058–4064. - PubMed
-
- Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer. 1988;61:209–220. - PubMed
-
- Maurer HM, Gehan EA, Beltangady M, et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer. 1993;71:1904–1922. - PubMed
-
- Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995;13:610–630. - PubMed
-
- Crist W, Anderson J, Meza JL, et al. The Intergroup Rhabdomyosarcoma Study-IV: results for patients with non-metastatic disease. J Clin Oncol. 2001;19:3091–3102. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources